Job Code 267MW
Fate Therapeutics is currently seeking a talented and highly motivated Scientist/Associate Scientist with a strong background in T cell and/or NK cell immunology. The Translational Science team designs and performs assays to measure the safety and efficacy of cellular immunotherapies for cancer including iPSC-derived NK cells, CAR-NK cells, and CAR-T cells. Successful candidates will have a background in studying the functions of T cells and/or NK cells in the fields of tumor immunology, autoimmune disease or infectious disease. The candidate will play a key role in developing novel translational science assays to study the function of T cells and NK cells. The candidate must have strong expertise in cell culture and functional immune assays. Desired skills include flow cytometry (phenotyping, intracellular cytokines, proliferation, etc), mixed lymphocyte reactions (MLR), antigen-specific T cell response assays, or NK cell functional assays. The position will require innovative thinking, strong independent and collaborative research abilities, and excellent oral and written communication skills. This is a full-time, bench-level position reporting to the Senior Scientist, Translational Medicine and is located at the Company’s corporate headquarters in San Diego, California.
Download a PDF of the job description for more details:
For consideration send cover letter and curriculum vitae to: firstname.lastname@example.org and reference job 267MW.
About Fate Therapeutics, Inc.
Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product candidate pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.